# Evaluation of a Third and Fourth Dose of StaphVAX® in Adults With End-Stage Renal Disease

> **NCT00130260** · PHASE3 · TERMINATED · sponsor: **Nabi Biopharmaceuticals** · enrollment: 99 (actual)

## Conditions studied

- Staphylococcal Infections
- Chronic Kidney Failure

## Interventions

- **BIOLOGICAL:** Staph aureus types 5 and 8 conjugate vaccine
- **BIOLOGICAL:** placebo

## Key facts

- **NCT ID:** NCT00130260
- **Lead sponsor:** Nabi Biopharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-08
- **Primary completion:** 2005-12
- **Final completion:** 2006-04
- **Target enrollment:** 99 (ACTUAL)
- **Why stopped:** unsatisfactory efficacy data from preceding trial
- **Last updated:** 2008-01-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00130260

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00130260, "Evaluation of a Third and Fourth Dose of StaphVAX® in Adults With End-Stage Renal Disease". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00130260. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*